Home › Funds › CAPSTONE INVESTMENT ADVISORS, LLC › XERS

CAPSTONE INVESTMENT ADVISORS, LLC position in XERS

Xeris Biopharma Holdings Inc · Health Care

CAPSTONE INVESTMENT ADVISORS, LLC reported holding 23,074,000 shares of XERS (Xeris Biopharma Holdings Inc) in its Q2 2026 13F filing — a position valued at US$62.6M, representing 0.77% of its reported portfolio and ranking #23 among its reported holdings. CAPSTONE INVESTMENT ADVISORS, LLC has disclosed XERS holdings in 6 of the last 6 reported quarters, going back to Q1 2025.

Latest position (Q2 2026)23.07M sh
Reported value held$62.64M
Portfolio Weight0.77%
First reportedQ1 2025
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How CAPSTONE INVESTMENT ADVISORS, LLC's XERS position evolved

CAPSTONE INVESTMENT ADVISORS, LLC first disclosed a stake in XERS in Q1 2025 at 20,900,000 shares (US$39.9M). The position peaked in Q2 2026 at 23,074,000 shares, worth US$62.6M. Across 6 filings, CAPSTONE INVESTMENT ADVISORS, LLC increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 23,074,000 shares valued at US$62.6M. Notable position changes include a 100% trim in Q3 2025 (shares fell 4% over the following quarter), a 134599% increase in Q4 2025 (shares fell 26% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2025 20.90M $39.89M New
Q2 2025 23.07M $39.20M Add
Q3 2025 17.13K $139.44K Reduce
Q4 2025 23.07M $61.07M Add
Q1 2026 23.07M $47.18M Hold
Q2 2026 23.07M $62.64M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About XERS and 13F data

XERS (Xeris Biopharma Holdings Inc) is a Health Care company. 52 other funds we track also report a position in XERS — the largest reported positions include Polar Asset Management Partners Inc. (US$28.8M), Rosalind Advisors, Inc. (US$23.0M), Parkman Healthcare Partners LLC (US$14.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding XERS

All XERS fund holders →

FAQ

How long has CAPSTONE INVESTMENT ADVISORS, LLC held XERS?

CAPSTONE INVESTMENT ADVISORS, LLC has disclosed XERS holdings in 6 of the last 6 reported quarters, going back to Q1 2025.

What is CAPSTONE INVESTMENT ADVISORS, LLC's current position in XERS?

As of Q2 2026, CAPSTONE INVESTMENT ADVISORS, LLC holds 23.07M shares of XERS (Xeris Biopharma Holdings Inc), valued at $62.64M, representing 0.77% of its reported portfolio and ranking #23.

Has CAPSTONE INVESTMENT ADVISORS, LLC been buying or selling XERS?

In the latest 13F filing (Q2 2026), CAPSTONE INVESTMENT ADVISORS, LLC held unchanged its position in XERS. The position peaked in Q2 2026 at 23.07M shares.

Which other funds hold XERS?

Other major institutional holders of XERS include Polar Asset Management Partners Inc., Rosalind Advisors, Inc., Parkman Healthcare Partners LLC, among 52 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.